Spero R Cataland
Overview
Explore the profile of Spero R Cataland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
73
Citations
1801
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Luskin M, Yin J, Lozanski G, Curran E, Malnassy G, Mrozek K, et al.
Cancer
. 2025 Feb;
131(4):e35750.
PMID: 39916320
Background: Acute lymphoblastic leukemia (ALL) in adults is aggressive, with long-term outcomes impacted by treatment resistance and toxicity. CD52 is expressed in most cases of B- and T-lineage ALL. Alemtuzumab,...
2.
Fatola A, Fatola A, Evans M, Brown J, Davis E, Johnson A, et al.
Blood Adv
. 2024 Dec;
9(2):417-424.
PMID: 39626301
Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody-mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab effect...
3.
4.
Cataland S, Coppo P, Scully M, Lammle B
Blood
. 2024 Jul;
144(11):1143-1152.
PMID: 38958481
In the 100 years since Eli Moschcowitz reported the first case of thrombotic thrombocytopenic purpura (TTP), there has been remarkable awareness and progress in the diagnosis and management of this...
5.
6.
Scully M, Antun A, Cataland S, Coppo P, Dossier C, Biebuyck N, et al.
N Engl J Med
. 2024 May;
390(17):1584-1596.
PMID: 38692292
Background: Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived products) administered as routine prophylaxis or...
7.
Abou-Ismail M, Zhang C, Presson A, Chaturvedi S, Antun A, Farland A, et al.
Res Pract Thromb Haemost
. 2024 Apr;
8(3):102388.
PMID: 38651093
Background: Mortality due to immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains significant. Predicting mortality risk may potentially help individualize treatment. The French Thrombotic Microangiopathy (TMA) Reference Score has not been externally...
8.
Kuter D, Cataland S, Broome C, Neunert C
Am J Hematol
. 2024 Mar;
PMID: 38459819
Please visit https://bit.ly/AJHpodcast to complete the accredited learning activity and receive CME credit or NCPD contact hours. Because immune-mediated rare blood disorders are uncommon, healthcare providers often lack the knowledge...
9.
Abou-Ismail M, Zhang C, Presson A, Chaturvedi S, Antun A, Farland A, et al.
Blood Adv
. 2023 Dec;
8(3):620-623.
PMID: 38100454
No abstract available.
10.
Abdelsamia M, Farid S, Dean S, Cataland S
Hematol Rep
. 2023 Sep;
15(3):518-523.
PMID: 37754669
Avatrombopag is a novel oral non-peptide thrombopoietin receptor agonist (TPO-RA) that was approved by the FDA as a second-line therapy for chronic immune thrombocytopenia (cITP). Avatrombopag has shown promising results...